These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 9152109)

  • 21. Cutaneous ulcerations and pustular psoriasis flare caused by recombinant interferon beta injections in patients with multiple sclerosis.
    Webster GF; Knobler RL; Lublin FD; Kramer EM; Hochman LR
    J Am Acad Dermatol; 1996 Feb; 34(2 Pt 2):365-7. PubMed ID: 8655728
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Immunotherapy of multiple sclerosis. Consensus and controversies].
    Hohlfeld R
    Nervenarzt; 1999 Apr; 70(4):297. PubMed ID: 10354989
    [No Abstract]   [Full Text] [Related]  

  • 23. T-cell interferon gamma receptor binding in interferon beta-1b-treated patients with multiple sclerosis.
    Bongioanni P; Lombardo F; Moscato G; Mosti S; Meucci G
    Arch Neurol; 1999 Feb; 56(2):217-22. PubMed ID: 10025427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Education and self-management of interferon beta-1b therapy for multiple sclerosis.
    Keating MM; Ostby PL
    J Neurosci Nurs; 1996 Dec; 28(6):350-2, 357-8. PubMed ID: 9007762
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New onset of rheumatoid arthritis during interferon beta-1B treatment in a patient with multiple sclerosis: comment on the case report by Jabaily and Thompson.
    Alsalameh S; Manger B; Kern P; Kalden J
    Arthritis Rheum; 1998 Apr; 41(4):754. PubMed ID: 9550494
    [No Abstract]   [Full Text] [Related]  

  • 26. Natural killer cells in relapsing-remitting MS: effect of treatment with interferon beta-1B.
    Kastrukoff LF; Morgan NG; Zecchini D; White R; Petkau AJ; Satoh J; Paty DW
    Neurology; 1999 Jan; 52(2):351-9. PubMed ID: 9932956
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nephrotic syndrome associated with interferon-beta-1b therapy for multiple sclerosis.
    Kumasaka R; Nakamura N; Shirato K; Fujita T; Murakami R; Shimada M; Nakamura M; Osawa H; Yamabe H; Okumura K
    Clin Exp Nephrol; 2006 Sep; 10(3):222-5. PubMed ID: 17009081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Current status of interferon beta-1b in multiple sclerosis therapy].
    Hartung HP
    Med Klin (Munich); 2001 Sep; 96 Suppl 1():11-6. PubMed ID: 11603110
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Emotional state of patients with relapsing-remitting MS treated with interferon beta-1b.
    Borràs C; Río J; Porcel J; Barrios M; Tintoré M; Montalban X
    Neurology; 1999 May; 52(8):1636-9. PubMed ID: 10331691
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Newer versus older treatments for relapsing-remitting multiple sclerosis.
    Weinstock-Guttman B; Cohen JA
    Drug Saf; 1996 Feb; 14(2):121-30. PubMed ID: 8852526
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Urinary myelin basic protein-like material in patients with multiple sclerosis during interferon beta-1b treatment.
    Whitaker JN; Layton BA; Bartolucci AA; Mitchell GW; Bashir K; Goodwin J; Kachelhofer RD
    Arch Neurol; 1999 Jun; 56(6):687-91. PubMed ID: 10369307
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of interferons in demyelinating diseases.
    Arnason BG; Toscas A; Dayal A; Qu Z; Noronha A
    J Neural Transm Suppl; 1997; 49():117-23. PubMed ID: 9266421
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Course of depression during the initiation of interferon beta-1a treatment for multiple sclerosis.
    Mohr DC; Likosky W; Dwyer P; Van Der Wende J; Boudewyn AC; Goodkin DE
    Arch Neurol; 1999 Oct; 56(10):1263-5. PubMed ID: 10520943
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical efficacy and safety of long-term immunomodulating therapy with interferon beta].
    Demina TL; Khachanova NV; Davydovskaia MV; Popova NF; Gusev EI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2008; 108(4):24-6. PubMed ID: 18567192
    [No Abstract]   [Full Text] [Related]  

  • 35. Acute delirium, delusion, and depression during IFN-beta-1a therapy for multiple sclerosis: a case report.
    Goëb JL; Cailleau A; Lainé P; Etcharry-Bouyx F; Maugin D; Duverger P; Gohier B; Rannou-Dubas K; Dubas F; Garré JB
    Clin Neuropharmacol; 2003; 26(1):5-7. PubMed ID: 12567157
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple sclerosis pathways: an innovative nursing role in disease management.
    Madonna MG; Keating MM
    J Neurosci Nurs; 1999 Dec; 31(6):332-5. PubMed ID: 10726241
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Blood levels of transforming growth factor-beta 1 (TGF-beta1) are elevated in both relapsing remitting and chronic progressive multiple sclerosis (MS) patients and are further augmented by treatment with interferon-beta 1b (IFN-beta1b).
    Nicoletti F; Di Marco R; Patti F; Reggio E; Nicoletti A; Zaccone P; Stivala F; Meroni PL; Reggio A
    Clin Exp Immunol; 1998 Jul; 113(1):96-9. PubMed ID: 9697990
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neutralising and binding anti-interferon-beta-I b (IFN-beta-I b) antibodies during IFN-beta-I b treatment of multiple sclerosis.
    Kivisäkk P; Alm GV; Tian WZ; Matusevicius D; Fredrikson S; Link H
    Mult Scler; 1997 Jun; 3(3):184-90. PubMed ID: 9310964
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiple sclerosis, interferon beta-1b and depression A prospective investigation.
    Feinstein A; O'Connor P; Feinstein K
    J Neurol; 2002 Jul; 249(7):815-20. PubMed ID: 12140662
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Side effect profile of interferon beta-1b in MS: results of an open label trial.
    Neilley LK; Goodin DS; Goodkin DE; Hauser SL
    Neurology; 1996 Feb; 46(2):552-4. PubMed ID: 8614531
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.